Who’s Hired? Former Actavis Chief Bisaro Lands A New Role
Key Roles At Viatris Also Unveiled
Industry veteran Paul Bisaro has joined the board of TherapeuticsMD and Mylan has announced new Viatris appointments, while Amneal brings in a new CFO at the same time as Fresenius Kabi’s biosimilars head exits the company.
You may also be interested in...
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.
Fresenius Kabi says a decision on damages stemming from its aborted takeover of troubled Akorn is expected imminently, but has underlined it will not reap enormous riches with a victory. Meanwhile, the German firm has just initiated Phase III trials for a key biosimilar candidate.